UTHR files 8-K — Item 2.02 Results of Operations

United Therapeutics Corporation (UTHR, $25.1B market cap) filed an 8-K SEC form (accession number 0001082554-26-000021) exclusively for Item 2.02 (Results of Operations and Financial Data), accepted by the SEC on May 6, 2026 at 06:31:29 ET.

What Was Filed

Per SEC plain-language rules, Item 2.02 filings require furnishing a public press release discussing a company’s operating results or financial condition for a completed fiscal period. This filing coincides with a contemporaneously submitted 10-Q quarterly report on EDGAR, per recent SEC filing records, and aligns with the May 6, 2026 UTHR earnings announcement referenced in public news wires.

The Disclosure

The Item 2.02 filing delivers high-level first-quarter 2026 financial results: UTHR reported $781.5 million in total revenue, missing the Wall Street consensus estimate of $797.4 million. The company did not disclose a finalized earnings per share (EPS) figure, against a consensus estimate of $7.00 per share. For large-cap biotech firms like UTHR, Item 2.02 filings typically include preliminary top-line results and high-level commercial updates, with full granular financial disclosures reserved for the accompanying 10-Q.

Cross-Reference to Prior Signals

This earnings filing follows immediate prior insider trading activity from Martine A. Rothblatt, UTHR’s Chairperson and CEO, on May 5, 2026—one full business day before the 8-K’s SEC acceptance. Rothblatt executed seven separate S-Sale transactions totaling 7,035 shares of common stock, with gross proceeds totaling approximately $4.05 million, at prices ranging from $568.36 to $577.26 per share. She also completed two pre-planned Rule 10b5-1 (M-exempt) trades of 9,500 shares each on the same day, at $146.03 per share, which are not tied to short-term market movements. Additionally, analyst ratings have remained static since May 1, 2026, with 2 Strong Buy, 9 Buy, and 4 Hold assignments across covering firms, with no new ratings updates issued ahead of the earnings filing.

What This Filing Does NOT Tell Us

1. Granular product segment revenue breakdowns, such as sales for lead commercial product Remodulin or other pipeline-derived therapies, which are typically only included in full quarterly financial filings rather than Item 2.02 press releases.

2. The finalized actual EPS figure for Q1 2026, as only the consensus estimate and a note that actual results were not reported in the initial Item 2.02 filing are provided.

3. Forward-looking guidance for Q2 2026 or full-year 2026 financials, a common addition to earnings releases for large-cap biotechs that is not referenced in the provided filing details.